Phaseline

Companies › TME Pharma

TME Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Olaptesed Pegol (A12)
Stromal cell-derived factor 1 inhibitor
CXCL12Phase 1GlioblastomaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04121455Olaptesed Pegol (A12)Phase 1GlioblastomaOncologyDec 2028

Targets

CXCL12 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.